Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$39.47
<$0.01(<0.01%)
At close: 4:00 PM EST
$39.47
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.85 - $46.67
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.13M
Market Cap
$3.73B
Enterprise Value$3.73B
Total Cash (Recent Filing)$190.68M
Total Debt (Recent Filing)$197.93M
Price to Earnings (P/E)51.6
Beta1.64
Next Earnings
May 11, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding88,114,426
10 Day Avg. Volume1,173,301
30 Day Avg. Volume1,131,844
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue23.58
Enterprise Value/Gross Profit24.25
Enterprise Value/Ebitda-83.15
Forecast
1Y Price Target
$49.33Price Target Upside24.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.41
Revenue Forecast (FY)$588.05M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAnalyst highlights rapid prescription uptake, an expanding prescriber base, and high patient conversion that suggest Yutrepia is driving new prostacyclin treatment starts and supporting stronger-than-expected revenue momentum.
Profitability And Earnings LeverageVery high gross margins combined with disciplined operating expenses and reported profitability create attractive earnings leverage that could draw interest from institutional and core healthcare investors.
Technology Differentiation And TolerabilityAnalyst and key opinion leaders note the proprietary PRINT inhalation technology produces more uniform, smaller particles that improve lung targeting, enable efficient high-dose titration, and reduce coughing compared with conventional dry powder inhalers.
Bears Say
Cash And Funding RiskCash resources appear limited relative to growth ambitions, creating the risk that additional financing will be required, which could dilute shareholders or constrain investment in commercial expansion.
Competitive Device Announcement RiskA partner's surprise unveiling of a new inhaled treprostinil device without supporting clinical data or direct comparisons has amplified investor concern about competitive dynamics and contributed to downward pressure on the share price.
Patent Litigation OverhangOngoing patent litigation over a key patent represents a material overhang that could trigger injunctions or label restrictions, increasing investor uncertainty and the potential for significant stock volatility.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.85 and its highest was $46.67 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.73B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 11, 2026 which is in 3 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 05, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.227 by -$0.077.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.37.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 88,114,426 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.15 in its last earnings report, missing expectations of $0.227. Following the earnings report the stock price went up 0.407%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.33 (24.99% Upside)
$49.33 (24.99% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 69.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.68%
12-Months-Change
Fundamentals
Return on Equity
-209.33%
Trailing 12-Months
Asset Growth
42.20%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear evidence of rapid, profitable scale: robust Q4 sales growth, consecutive profitable quarters, meaningful cash generation, accelerating patient starts and prescriber adoption, and a pipeline of label- and market-expanding studies including a next-generation product. Risks highlighted include unresolved litigation, modest expected gross-to-net pressure as access expands, distributor inventory timing variability, and ongoing competitive entrants (oral agents and alternate inhaler formats). Management presented confident mitigation plans (expanded sales force, clinical transition studies, L606 development) and indicated operational cash funding for trials.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$49.33
▲(24.99% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
23.95% Insiders
7.53% Mutual Funds
1.45% Other Institutional Investors
57.36% Public Companies and Individual Investors